Tharimmune, INC 8-K filings

Tharimmune, Inc. has entered into a private placement agreement to raise approximately $2.5 million through the issuance of common stock and various warrants, earmarked for clinical development and working capital.

Tharimmune, Inc. announced the immediate resignation of its Chief Financial Officer, Don Kim, citing personal reasons.

Tharimmune, Inc. announced significant leadership changes, including the immediate resignation of CEO Randy Milby, the appointment of Sireesh Appajosyula as the new CEO, and the formalization of Vincent LoPriore's role as Executive Chairman, alongside a new board member.

Tharimmune, Inc. announced the successful outcomes of its Annual Meeting of Stockholders held on June 10, 2025, where all director nominees were elected, the independent auditor was ratified, and the amended 2023 Omnibus Equity Incentive Plan was approved.

Tharimmune, Inc. announced the appointment of Vincent LoPriore as Executive Chairman of the Board, effective immediately, replacing Randy Milby.

Tharimmune Inc. announces the appointment of Clay Kahler and Gary Stetz to its Board of Directors, increasing its size to nine members, effective April 28, 2025.

Leonard Mazur and Lynne Bui, MD, will retire from Tharimmune's Board of Directors at the company's 2025 Annual Meeting of Stockholders.

Tharimmune, Inc. has increased its Board of Directors to seven members with the appointment of Vincent LoPriore, effective April 9, 2025.

Tharimmune, Inc. received a Nasdaq notice on April 1, 2025, indicating non-compliance with the minimum stockholders' equity requirement for continued listing.

Tharimmune, Inc. announces the resignation of CFO Thomas Hess and the appointment of Don Kim as his successor, effective March 2025.

Tharimmune, a clinical-stage biotech firm, has successfully raised approximately $2.02 million through a private placement to advance its clinical development programs.

Tharimmune Inc. increased its board size and terminated a non-binding letter of intent to merge with Intract Pharma Ltd.

Tharimmune and Intract Pharma have signed a non-binding letter of intent to merge, aiming to create a leading oral biologics company.

Tharimmune has secured a global license to develop and commercialize an oral formulation of infliximab through a partnership with Intract Pharma.

Tharimmune, a clinical-stage biotech company, has announced a $2.08 million private placement to fund clinical development and working capital, particularly for its TH104 program.

Tharimmune, Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Tharimmune, Inc. has entered into an At-the-Market Offering Agreement with Rodman & Renshaw LLC to potentially sell shares of its common stock.

Tharimmune, Inc. has announced a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective May 24, 2024.

Tharimmune, Inc. successfully held its Annual Meeting of Stockholders, electing all director nominees and approving key proposals including a potential reverse stock split.

Tharimmune Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of outstanding shares.

Tharimmune, Inc. disclosed that it has 11,739,676 shares of common stock issued and outstanding as of February 8, 2024.